Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Omeros Corporation
  6. Company
    OMER   US6821431029

OMEROS CORPORATION

(OMER)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
Logo Omeros Corporation
Omeros Corporation is a commercial-stage biopharmaceutical company. The Company is engaged in discovering, developing and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting inflammation, complement-mediated diseases and disorders of the central nervous system. The Company’s drug product OMIDRIA (phenylephrine and ketorolac intraocular solution) is used during cataract surgery or intraocular lens (IOL) replacement. The Company’s clinical-stage development programs are focused on complement-associated thrombotic microangiopathies, complement-mediated glomerulonephropathies, Huntington’s disease and cognitive impairment, and addictive and compulsive disorders. It also offers a diverse group of preclinical programs and platforms that are used to unlock new G protein-coupled receptor (GPCR) drug targets and to generate antibodies.

Number of employees : 277 people.
Sales per Business
20192020Delta
Small-Molecule and Protein Therapeutics111.81100%73.81100% -33.98%
USD in Million
Sales per region
20192020Delta
United States111.81100%73.81100% -33.98%
USD in Million
Managers
Name Title Age Since
Gregory A. Demopulos, Dr. Chairman, President & Chief Executive Officer 61 2009
Michael A. Jacobsen Chief Financial Officer, Treasurer & VP 61 2013
George A. Gaitanaris, Dr. Chief Scientific Officer & Vice President-Science 63 2012
J. Steven Whitaker, Dr. Chief Medical Officer & Vice President 64 2019
Ray Aspiri Independent Director 83 1995
Thomas J. Cable Lead Independent Director 80 1995
Leroy E. Hood, Dr. Independent Director 81 2001
Arnold C. Hanish Independent Director 72 2012
Rajiv J. Shah, Dr. Independent Director 47 2015
Thomas F. Bumol, Dr. Independent Director 66 2019
Members of the board
Name Title Age Since
Gregory A. Demopulos, Dr. Chairman, President & Chief Executive Officer 61 2009
Ray Aspiri Independent Director 83 1995
Thomas J. Cable Lead Independent Director 80 1995
Peter A. Demopulos, Dr. Director 66 1995
Leroy E. Hood, Dr. Independent Director 81 2001
Arnold C. Hanish Independent Director 72 2012
Rajiv J. Shah, Dr. Independent Director 47 2015
Thomas F. Bumol, Dr. Independent Director 66 2019
Kurt Zumwalt Independent Director 51 2020
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 62,328,370 59,748,633 95.9% 0 0.0% 95.9%
Shareholders
NameEquities%
Ingalls & Snyder LLC 4,319,792 6.93%
Cormorant Asset Management LP 3,300,030 5.29%
The Vanguard Group, Inc. 3,158,948 5.07%
D. E. Shaw & Co. LP 2,711,960 4.35%
Gregory A. Demopulos 2,026,986 3.25%
Fidelity Management & Research Co. LLC 1,873,939 3.01%
BlackRock Fund Advisors 1,707,397 2.74%
SSgA Funds Management, Inc. 1,293,301 2.07%
Geode Capital Management LLC 994,915 1.60%
Stifel Nicolaus & Co., Inc. (Investment Management) 953,011 1.53%
Company contact information
Omeros Corp.
The Omeros Building
201 Elliott Avenue West
Seattle, WA 98119

Web : http://www.omeros.com
Sector Bio Therapeutic Drugs
1st jan.Capi. (M$)
OMEROS CORPORATION-0.67%973
GILEAD SCIENCES, INC.18.47%85 134
WUXI APPTEC CO., LTD.37.17%71 226
REGENERON PHARMACEUTICALS21.37%57 013
BIONTECH SE245.88%55 555
VERTEX PHARMACEUTICALS-15.16%50 308
BEIGENE, LTD.22.66%33 627
GENMAB A/S15.31%27 394
ARGENX SE10.70%16 311
HUALAN BIOLOGICAL ENGINEERING INC.-9.75%10 439
NEUROCRINE BIOSCIENCES, INC.2.79%9 482
ARROWHEAD PHARMACEUTICALS, INC.-10.90%9 401
DENALI THERAPEUTICS INC.-23.71%9 051
MIRATI THERAPEUTICS, INC.-28.46%8 451
FATE THERAPEUTICS, INC.-5.21%7 951
REMEGEN CO., LTD.0.58%7 820
ACCELERON PHARMA INC.-4.01%7 722
ASCENDIS PHARMA A/S-30.65%7 555
EXELIXIS, INC.-16.64%7 340
GW PHARMACEUTICALS PLC89.72%6 907
AKESO, INC.39.34%6 690